PMID- 21872908
OWN - NLM
STAT- MEDLINE
DCOM- 20120611
LR  - 20181201
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 128
IP  - 6
DP  - 2011 Dec
TI  - Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay 
      with two commercial anti-FXa chromogenic assays.
PG  - e166-70
LID - 10.1016/j.thromres.2011.08.002 [doi]
AB  - INTRODUCTION: Fast and accurate monitoring is crucial in the successful 
      regulation of coagulation therapy. For the treatment of venous thromboembolism, 
      both unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are 
      commonly administered. The chromogenic anti-factor Xa (FXa) assay is currently 
      considered the 'gold standard' assay for monitoring LMWH. However different 
      commercial chromogenic methods often differ when tested with the same samples. 
      Fluorogenic anti-FXa assays have the potential to offer greater benefits over 
      chromogenic assays in terms of greater specificity, sensitivity and they are not 
      so influenced by sample opacity or turbidity. MATERIALS AND METHODS: Commercial 
      plasmas were spiked with pharmacologically relevant concentrations (0-1 U/ml) of 
      UFH, enoxaparin, and tinzaparin. The fluorogenic assay was carried out using 
      previously optimized concentrations of 12 nM FXa and 2.7muM fluorogenic substrate, 
      in addition to 6mul of 100mM CaCl(2) and 44mul of plasma. The Biophen(R) and Coamatic 
      chromogenic assays were carried out according to the manufacturer's instructions. 
      Reaction rates and endpoint values were analyzed and statistical analysis by 
      means of one-way analysis of variance (ANOVA) was performed. RESULTS: The 
      fluorogenic anti-FXa assay was found to have the broadest therapeutic range of 
      0-1 U/ml with CVs of<5% for UFH and tinzaparin and CVs<9% for enoxaparin. Despite 
      their limited measuring range, good assay reproducibility was observed with both 
      chromogenic kits. CONCLUSIONS: This study indicated that the fluorogenic assay is 
      the most sensitive assay with the broadest dynamic range for monitoring LMWH 
      therapy when compared with standard chromogenic assays.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Harris, Leanne F
AU  - Harris LF
AD  - Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin 
      City University, Dublin 9, Ireland.
FAU - O'Brien, Aoife
AU  - O'Brien A
FAU - Castro-Lopez, Vanessa
AU  - Castro-Lopez V
FAU - O'Donnell, James S
AU  - O'Donnell JS
FAU - Killard, Anthony J
AU  - Killard AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110827
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Anticoagulants/blood/chemistry/pharmacology
MH  - Chemistry Techniques, Analytical/*methods
MH  - Enoxaparin/blood
MH  - Factor Xa/chemistry/isolation & purification
MH  - *Factor Xa Inhibitors
MH  - Fluorescent Dyes/chemistry
MH  - Heparin/blood/chemistry/*pharmacology
MH  - Heparin, Low-Molecular-Weight/blood/chemistry/*pharmacology
MH  - Humans
MH  - Tinzaparin
EDAT- 2011/08/30 06:00
MHDA- 2012/06/12 06:00
CRDT- 2011/08/30 06:00
PHST- 2011/02/01 00:00 [received]
PHST- 2011/07/22 00:00 [revised]
PHST- 2011/08/02 00:00 [accepted]
PHST- 2011/08/30 06:00 [entrez]
PHST- 2011/08/30 06:00 [pubmed]
PHST- 2012/06/12 06:00 [medline]
AID - S0049-3848(11)00424-5 [pii]
AID - 10.1016/j.thromres.2011.08.002 [doi]
PST - ppublish
SO  - Thromb Res. 2011 Dec;128(6):e166-70. doi: 10.1016/j.thromres.2011.08.002. Epub 
      2011 Aug 27.